Ibrutinib holds CLL at bay in majority of patients at 30 months

The most common side effects were hypertension and pneumonia.

The PCYC-1002 and -1003 studies were supported by Pharmacyclics. Dr. O’Brien disclosed receiving research funding from the company. Dr. Lamanna disclosed consulting/advising for Celgene, and receiving research funding from several companies, but not Pharmacyclics.